Diabetes: New insulin sensitizers discovered

October 24, 2017, Columbia University Medical Center

A root cause of type 2 diabetes is a condition known as insulin resistance, in which cells stop responding to commands from the hormone that regulates glucose (sugar) storage. Restoring insulin sensitivity can be an effective strategy for preventing and treating diabetes, but the only insulin-sensitizing drugs on the market also stimulate the production of lipids (fats), which can lead to a number of serious side effects.

A new study, led by researchers at Columbia University Medical Center, indicates that it may be possible to improve while avoiding these adverse effects. The findings were published online in Cell.

Insulin, a hormone made in the pancreas, signals cells to grab glucose out of the bloodstream and use it for energy. When cells become resistant to insulin, glucose accumulates in the bloodstream. Eventually, insulin resistance can lead to diabetes.

"Researchers have been looking for ways to overcome insulin resistance without inadvertently triggering fat accumulation," said study leader Domenico Accili, MD, the Russell Berrie Foundation Professor of Diabetes and director of the Columbia University Diabetes Research Center at CUMC. "But previous efforts have been unsuccessful."

One approach that has been studied is to inhibit a protein called FOXO1. Animal studies have shown that when FOXO1 is suppressed, the liver makes less glucose. But like other insulin sensitizers, inhibiting FOXO1 also stimulates the production of lipids. "Thus, treatment of with a broadly acting FOXO1 inhibitor can lead to a host of unwanted side effects, such as weight gain," said Dr. Accili. "Unfortunately, with FOXO1 insulin sensitizers, you get the good with the bad."

In the current study, the researchers looked for a way to partially inhibit FOXO1 so that declined but lipid levels were unaffected. "What we needed to understand is how the two FOXO1-mediated mechanisms differ, so that we could identify selective inhibitors," said co-author Daniel Lindén, a scientist with AstraZeneca's Innovative Medicines and Early Development biotech Unit in Gothenburg, Sweden.

In studies performed in mice, Dr. Accili and his colleagues discovered that FOXO1 works with a protein called SIN3A to limit lipid production. "This suggested that if we could find molecules that act on the glucose-production arm of FOXO1 while leaving SIN3A alone, we could improve insulin sensitivity and lower blood sugar without increasing fat," said Dr. Accili.

From a screen of one million small molecules, the team identified several with the desired effect in liver cells. They went on to characterize three of these molecules in greater detail—potentially paving the way for the development of a new class of sensitizers.

"The next step is to optimize these compounds for animal testing and lay the groundwork for clinical trials," said Dr. Accili. "We're excited by the possibility of developing a new and safer way to treat ."

Explore further: A new approach to treating type I diabetes? Gut cells transformed into insulin factories

More information: Cell (2017). DOI: 10.1016/j.cell.2017

Related Stories

A new approach to treating type I diabetes? Gut cells transformed into insulin factories

March 11, 2012
A study by Columbia researchers suggests that cells in the patient's intestine could be coaxed into making insulin, circumventing the need for a stem cell transplant. Until now, stem cell transplants have been seen by many ...

Study explains decrease in insulin-producing beta cells in diabetes

September 13, 2012
Scientists generally think that reduced insulin production by the pancreas, a hallmark of type 2 diabetes, is due to the death of the organ's beta cells. However, a new study by Columbia University Medical Center (CUMC) researchers ...

Intestinal glucose stimulation has anti-incretin effect

September 13, 2017
(HealthDay)—Intestinal glucose stimulation has an anti-incretin effect, down regulating insulin sensitivity, according to a study published online Aug. 29 in Diabetes.

It may take guts to cure diabetes: Human GI cells retrained to produce insulin

June 30, 2014
By switching off a single gene, scientists at Columbia University's Naomi Berrie Diabetes Center have converted human gastrointestinal cells into insulin-producing cells, demonstrating in principle that a drug could retrain ...

Insulin signaling molecule in liver controls levels of triglyceride in blood

October 19, 2017
A new animal study shows how insulin controls the movement and storage of fat molecules in the liver and how a breakdown in this system could lead to non-alcoholic fatty liver disease and changes in circulating lipid levels ...

Study reveals how FOXO1 slows diabetic wound healing

April 27, 2015
A protein that normally fosters tissue repair instead acts to inhibit healing when sugar levels are high, according to a study in The Journal of Cell Biology. The role reversal helps explain why wounds heal slowly in people ...

Recommended for you

Diabetic foot ulcers heal quickly with nitric oxide technology

November 12, 2018
Diabetic foot ulcers can take up to 150 days to heal. A biomedical engineering team wants to reduce it to 21 days.

Diabetes drug might also ease heart failure risks

November 12, 2018
(HealthDay)—The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows.

Marijuana use tied to serious diabetes complication

November 8, 2018
(HealthDay)—People with type 1 diabetes who use marijuana may double their risk of developing a life-threatening complication, a new study suggests.

Researchers report connection between intestinal bacteria and development of diabetes

November 7, 2018
Researchers at Örebro University have, together with a well-known research team in Denmark, developed a method for studying how metabolism in gut bacteria influences health. Their method will now be published in its entirety ...

Genetic factors tied to obesity may protect against diabetes

November 2, 2018
Some genetic variations linked with obesity actually protect against Type 2 diabetes, heart attack and stroke, new findings suggest.

Study shows improved health, reduced overweight and obesity in Pacific-region children

October 30, 2018
A community-randomized clinical trial of the Children's Healthy Living Program (CHL), based at the University of Hawaiʻi at Mānoa, seeking to sustainably prevent and decrease overweight and obese young children and to improve ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.